Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can targeted radiation retrain recurrent brain tumors?

NCT ID NCT05081908

Disease control Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 31, 2026 · Last updated Sep 01, 2026 · Updated 1 time

Summary

This trial tests whether multisession radiosurgery, a type of focused radiation delivered in several sessions using the Cyberknife system, can safely control atypical meningiomas that remain or come back after surgery. The study enrolls adults with grade II meningiomas who have residual or recurrent tumors. Researchers will track neurological side effects and measure tumor response using MRI scans to see if the treatment stabilizes or shrinks the lesions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Multisession radiosurgery (hypofractionated radiotherapy) delivered with Cyberknife
What this could lead to
If it works, this approach could offer a safe way to control atypical meningiomas that remain or return after surgery, potentially delaying the need for more invasive treatments.
What could go wrong
This is a small feasibility study, so results may not apply broadly. The treatment may cause neurological side effects, and it is not yet clear how well it controls tumor growth over the long term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

25 people

The number who actually took part.

Started

May 2017

Finished

May 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients had residual or recurrent atypical meningioma (grade II) after surgery (Simpson score) * Age: ≥ 18 years old * Karnofsky performance Status ( KPS) ≥ 70 * Written consent Exclusion Criteria: * Pregnancy * Neurofibromatosis type 2 (NF2) * Concomitant aggressive haematological or solid neoplasm

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Meningioma atypical are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

grade II meningioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Meningioma atypical

Contacts and locations

Locations

  • UOC Radioterapia

    Milan, Milano, 20133, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.